Business Corpus: This Biotech Stock Flew 40% On Its Postpartum Depression TreatmentSage Therapeutics skyrocketed more than 40% Monday after its postpartum depression treatment showed promise in a Phase 3 study. Sage is also studying SAGE-217 in major depressive disorder. The post This Biotech Stock Flew 40% On Its Postpartum Depression Treatment appeared first on Investor's Business Daily.

[Collection]

Sage Therapeutics (SAGE) skyrocketed more than 50% Monday after its postpartum depression treatment showed promise in a Phase 3 study.

In morning trades on the stock market today, Sage stock soared 55%, near 150.50.

The biotech tested a 30-milligram dose of its postpartum depression treatment, SAGE-217, over the course of two weeks. The drug improved symptoms of depression on the Hamilton Rating Scale of Depression by 17.8 points vs. 13.6 points for the placebo.

Additionally, 45% of patients achieved remission at two weeks as measured by the same scale. Just 23% of those who received the placebo were in remission at two weeks.

"These are strong and consistent data demonstrating a rapid, stable and clinically meaningful improvement in postpartum depression symptoms in the SAGE-217 treatment group compared to the placebo," Chief Executive Jeff Jonas said in a prepared statement.

SAGE-217 is just one in a broader pipeline of drugs to treat postpartum depression. Sage's lead postpartum depression treatment, Zulresso, is currently under review at the Food and Drug Administration. Tests also are underway on SAGE-217 for major depressive disorder.

YOU MIGHT ALSO LIKE:

Can CRISPR And These 3 Small Biotechs Cure 10,000 Diseases?

Looking For Growth? Take A Look At These Biotechnology Stocks

CAN SLIM Trading: Can You Make Big Profits With Just A Little Cash? Yes, Here's The Way

The post This Biotech Stock Flew 40% On Its Postpartum Depression Treatment appeared first on Investor's Business Daily.